Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation

CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed...

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

International recognition of quality system with GMP-compliance in the key markets of Brazil, Indonesia, Egypt, Colombia and Argentina Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory...

Modern Dairy Wins Six Awards in Extel's 2025 Asia (ex-Japan) Executive Team Rankings

Modern Dairy Wins Six Awards in Extel's 2025 Asia (ex-Japan) Executive Team Rankings

HONG KONG, May 20, 2025 /PRNewswire/ -- On May 20, the prestigious financial magazine "Extel" (formerly "Institutional Investor") officially announced the results of the "2025 Asia (ex-Japan) Executive Team-SMID" rankings. The survey assessed and...

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider...

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced...

2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations

2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations

MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency. The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity. With various TCMs, the...

Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services

Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services

This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance Clinical...

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections Demonstrated its Efficacy and Safety through previous Clinical Trials Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May...

Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy

Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy

Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea, May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND)...

Care Begins Within Because Ingredients Matter: Lenzing's VEOCEL™ Champions Sustainable Innovation at IDEA25 and CIDPEX

Care Begins Within Because Ingredients Matter: Lenzing's VEOCEL™ Champions Sustainable Innovation at IDEA25 and CIDPEX

VEOCEL™ highlighted its innovative, environmentally responsible fibers for hygiene and personal care single-use products at CIDPEX and IDEA25 With VEOCEL™ Lyocell, Lenzing invites partners to unleash possibilities in single-use – not only meeting...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • menu
    menu